Clinical Trial Update: EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gefitinib plus thalidomide in EGFR-mutant non-small cell lung cancer. The current status of the trial is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gefitinib (Gefitinib)
• Thalidomide (thalidomide)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: NSCLC Stage IV, Chemotherapy Effect | Phase 2 | Status: UNKNOWN